Orvida Pharma Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Kamari Pharma Ltd. (to 2026)
4
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 7, 2027The maintenance fee for Compounds and Compositions for Use in Treating Skin Disorders (US 11,807,621) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,389,546 | Compounds for Modulating TRPV3 Function In force · High confidence | In force | High confidence | |
| US 9,181,219 | Compounds of Modulating TRPV3 Function In force · High confidence | In force | High confidence | |
| US 7,893,260 | Substituted QUINAZOLIN-4-ONE Compounds for Antagonizing TRPV3 Function In force · High confidence | In force | High confidence | |
| US 7,998,980 | Compounds for Modulating TRPV3 Function In force · High confidence | In force | High confidence | |
| US 12,435,061 | Compounds and Compositions for Use in Treating Skin Disorders In force · High confidence | In force | High confidence | |
| US 11,807,621 | Compounds and Compositions for Use in Treating Skin Disorders In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.